High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity-Reference-Cited by-同舟云学术

High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity

Published:2021-09-01 Issue:9 Volume:7 Page:1322
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Martin Allison M.¹,Jackson Sadhana²³

Affiliation:

1. Department of Pediatrics, Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York

2. Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

3. Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2782039/jamaoncology_martin_2021_ic_210008_1631288610.86378.pdf

Reference8 articles.

1. Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the Children’s Oncology Group.;Leary;JAMA Oncol

2. High incidence of veno-occlusive disease with myeloablative chemotherapy following craniospinal irradiation in children with newly diagnosed high-risk CNS embryonal tumors: a report from the Children’s Oncology Group (CCG-99702).;Nazemi;Pediatr Blood Cancer,2016

3. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children’s Oncology Group Phase I/II study.;Jakacki;J Clin Oncol,2012

4. Extensive molecular and clinical heterogeneity in patients with histologically diagnosed CNS-PNET treated as a single entity: a report from the Children’s Oncology Group Randomized ACNS0332 Trial.;Hwang;J Clin Oncol,2018

5. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.;Ellison;Acta Neuropathol,2011